(Q24244924)

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Unjustified exclusion of elderly people from studies submitted to research ethics committee for approval: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Exclusion of elderly people from clinical research: a descriptive study of published reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

The treatment of operable breast cancer in the elderly female

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Management of breast cancer in the elderly by complete local excision and tamoxifen alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

The effect of comorbidity on 3-year survival of women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Breast cancer care in old age: what we know, don't know, and do.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

The importance of the lumpectomy surgical margin status in long-term results of breast conservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Is surgical management compromised in elderly patients with breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

The need for targeted research into breast cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Stage and treatment variation with age in postmenopausal women with breast cancer: compliance with guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Indications for primary tamoxifen therapy in elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Breast carcinoma in the elderly patient: An assessment of operative risk, morbidity and mortality

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Tumor characteristics and clinical outcome of elderly women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Relationship of age and menopausal status to estrogen receptor content in primary carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

What threshold for adjuvant therapy in older breast cancer patients?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004272.PUB2

7 January 2021